Clinical Trial Update: Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the combination of cabozantinib with Lutetium-177 DOTATATE in neuroendocrine tumors expressing somatostatin receptor 2, and the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Providence Health & Services | Conditions: Neuroendocrine Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING